Skip to main content
SpringerLink
Log in

Bladder Cancer Radiotherapy

  • Chapter
  • First Online:
Radiation Therapy for Genitourinary Malignancies

Part of the book series: Practical Guides in Radiation Oncology ((PGRO))

  • 655 Accesses

Abstract

Urothelial (transitional cell) carcinoma is the most common histologic subtypes of bladder cancer and can originate anywhere there is transitional epithelium. However, >90% of urothelial carcinomas arise in the urinary bladder. Bladder cancer more commonly affects the elderly population. Some preventable risk factors for developing bladder cancer include but are not limited to cigarette smoking, environmental/occupational exposures (paints, hair dyes), exposure to certain drugs (cyclophosphamide), and prior radiation therapy to the pelvis. This chapter summarizes some of the critical aspects of management of bladder cancer with radiotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424

    Article  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–34

    Article  Google Scholar 

  3. Cancer Stat Facts: Bladder Cancer (2019) NIH NCI: Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed 2 Mar 2019

  4. European Association of Eurology (2019) Non-muscle-invasive bladder cancer. https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer. Accessed 2 Mar 2019

  5. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: bladder cancer, v.1.2019. https://www.nccn.org/professionals/physician_gls/pdf/bladder_blocks.pdf. Accessed 2 Mar 2019

  6. Amin MB, Edge SB, Greene F et al (eds) (2017) AJCC cancer staging manual, 8th edn. Springer International Publishing, New York

    Google Scholar 

  7. Mak RH, Hunt D, Shipley WU et al (2014) Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 32(34):3801

    Article  Google Scholar 

  8. Giacalone NJ, Shipley WU, Clayman RH et al (2017) Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience. Eur Urol 71(6):952–960

    Article  Google Scholar 

  9. Kulkarni GS, Hermanns T, Wei Y et al (2017) A propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer. J Clin Oncol 35(20):2299–2305

    Article  Google Scholar 

  10. Chang SS, Bochner BH, Chou R et al (2017) Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol 198(3):552–559

    Article  Google Scholar 

  11. Tester W, Porter A, Asbell S et al (1993) Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 25(5):783–790

    Article  CAS  Google Scholar 

  12. Tester W, Caplan R, Heaney J et al (1996) Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 14(1):119–126

    Article  CAS  Google Scholar 

  13. Shipley WU, Winter KA, Kaufman DS et al (1998) Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16(11):3576–3583

    Article  CAS  Google Scholar 

  14. Kaufman DS, Winter KA, Shipley WU et al (2000) The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 5(6):471–476

    Article  CAS  Google Scholar 

  15. Hagan MP, Winter KA, Kaufman DS et al (2003) RTOG 97-06: initial report of a phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 57(3):665–672

    Article  Google Scholar 

  16. Kaufman DS, Winter KA, Shipley WU et al (2009) Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 73(4):833–837

    Article  Google Scholar 

  17. Gogna NK, Matthews JH, Turner SL et al (2006) Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential phase II studies from the Trans Tasman Radiation Oncology Group. Radiother Oncol 81(1):9–17

    Article  CAS  Google Scholar 

  18. James ND, Hussain SA, Hall E et al (2012) Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366(16):1477–1488

    Article  CAS  Google Scholar 

  19. Coen JJ, Zhang P, Saylor PJ et al (2019) Bladder preservation with twice-a-day radiation plus fluorouracil/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG/RTOG 0712—a randomized phase II trial. J Clin Oncol 37(1):44

    Article  CAS  Google Scholar 

  20. Chemoradiotherapy with or without atezolizumab in treating patients with localized muscle invasive bladder cancer (2019). https://clinicaltrials.gov/ct2/show/NCT03775265 (Identification No. NCT03775265)

  21. Baumann BC, Bosch WR, Bahl A et al (2016) Development and validation of consensus contouring guidelines for adjuvant radiation therapy for bladder cancer after radical cystectomy. Int J Radiat Oncol Biol Phys 96(1):78–86

    Article  Google Scholar 

  22. Duchesne GM, Bolger JJ, Griffiths GO et al (2000) A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. Int J Radiat Oncol Biol Phys 47(2):379–388

    Article  CAS  Google Scholar 

  23. Efstathiou JA, Bae K, Shipley WU et al (2009) Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 27(25):4055

    Article  CAS  Google Scholar 

  24. Zietman AL, Sacco D, Skowronski URI et al (2003) Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 170(5):1772–1776

    Article  Google Scholar 

  25. Huddart RA, Hall E, Lewis R et al (2020) Patient-reported quality of life outcomes in patients treated for muscle-invasive bladder cancer with radiotherapy ± chemotherapy in the BC2001 phase III randomised controlled trial. Eur Urol 77(2):260–268

    Google Scholar 

  26. Mak KS, Smith AB, Eidelman A et al (2016) Quality of life in long-term survivors of muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 96(5):1028–1036

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Baylor Scott and White Health, Temple, TX, USA

    Sameer Jhavar

  2. Department of Radiation Oncology, Joe Arrington Cancer Research and Treatment Center, Covenant Health, Lubbock, TX, USA

    Gabriel Axelrud

  3. Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Jason A. Efstathiou

Authors
  1. Sameer Jhavar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gabriel Axelrud
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jason A. Efstathiou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sameer Jhavar .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Loyola University Chicago, Maywood, IL, USA

    Abhishek A. Solanki

  2. Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS, USA

    Ronald C. Chen

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Jhavar, S., Axelrud, G., Efstathiou, J.A. (2021). Bladder Cancer Radiotherapy. In: Solanki, A.A., Chen, R.C. (eds) Radiation Therapy for Genitourinary Malignancies . Practical Guides in Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-65137-4_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-65137-4_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-65136-7

  • Online ISBN: 978-3-030-65137-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation